Stocks
News
ETFs
Economy
Currencies
Press Releases
Articles from AB Science
AB Science today provides an update on its masitinib platform
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 29, 2025
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 24, 2025
AB Science will participate in the Biomed Forum investors conference
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 22, 2025
AB Science provides a summary of the webcast held on December 16, 2024
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 17, 2024
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 11, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· October 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· October 17, 2024
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· October 10, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial report
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 30, 2024
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 26, 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 23, 2024
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· July 8, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· June 28, 2024
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 31, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 29, 2024
AB Science reports its revenues for the year 2023 and provides an update on its activities
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 15, 2024
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 13, 2024
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 7, 2024
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 2, 2024
AB Science announces a slight delay in the publication of its 2023 annual financial report
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· April 30, 2024
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 13, 2024
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 7, 2024
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 6, 2024
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 1, 2024
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· February 29, 2024
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· February 26, 2024
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 26, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 15, 2024
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· November 27, 2023
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 29, 2023
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 18, 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· June 26, 2023
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· June 1, 2023
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
By
AB Science
· Via
GlobeNewswire
· May 17, 2023
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· May 9, 2023
AB Science reports its revenues for the year 2022 and provides an update on its activities
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· April 28, 2023
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· April 27, 2023
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· April 18, 2023
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
By
AB Science
· Via
GlobeNewswire
· April 12, 2023
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· April 4, 2023
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 15, 2023
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· March 13, 2023
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· February 28, 2023
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· January 31, 2023
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 29, 2022
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 27, 2022
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 22, 2022
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· December 13, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· November 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· October 10, 2022
AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
PRESS RELEASE
By
AB Science
· Via
GlobeNewswire
· September 30, 2022
